Vincerx Pharma Inc Stock News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to learn more about their le...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transa...

Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline

Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 2024